Literature DB >> 24648338

The A4 study: stopping AD before symptoms begin?

Reisa A Sperling1, Dorene M Rentz, Keith A Johnson, Jason Karlawish, Michael Donohue, David P Salmon, Paul Aisen.   

Abstract

A new secondary prevention trial in older people with amyloid accumulation at high risk for Alzheimer's disease dementia should provide insights into whether anti-amyloid therapy can delay cognitive decline.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24648338      PMCID： PMC4049292          DOI： 10.1126/scitranslmed.3007941

Source DB:  PubMed          Journal:  Sci Transl Med        ISSN： 1946-6234            Impact factor:   17.956


  10 in total

1.  Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.

Authors:  Reisa A Sperling; Paul S Aisen; Laurel A Beckett; David A Bennett; Suzanne Craft; Anne M Fagan; Takeshi Iwatsubo; Clifford R Jack; Jeffrey Kaye; Thomas J Montine; Denise C Park; Eric M Reiman; Christopher C Rowe; Eric Siemers; Yaakov Stern; Kristine Yaffe; Maria C Carrillo; Bill Thies; Marcelle Morrison-Bogorad; Molly V Wagster; Creighton H Phelps
Journal:  Alzheimers Dement       Date:  2011-04-21       Impact factor: 21.566

Review 2.  Testing the right target and right drug at the right stage.

Authors:  Reisa A Sperling; Clifford R Jack; Paul S Aisen
Journal:  Sci Transl Med       Date:  2011-11-30       Impact factor: 17.956

3.  Face-name associative memory performance is related to amyloid burden in normal elderly.

Authors:  Dorene M Rentz; Rebecca E Amariglio; J Alex Becker; Meghan Frey; Lauren E Olson; Katherine Frishe; Jeremy Carmasin; Jacqueline E Maye; Keith A Johnson; Reisa A Sperling
Journal:  Neuropsychologia       Date:  2011-06-12       Impact factor: 3.139

4.  Risk disclosure and preclinical Alzheimer's disease clinical trial enrollment.

Authors:  Joshua D Grill; Jason Karlawish; David Elashoff; Barbara G Vickrey
Journal:  Alzheimers Dement       Date:  2012-11-08       Impact factor: 21.566

5.  Regulatory innovation and drug development for early-stage Alzheimer's disease.

Authors:  Nicholas Kozauer; Russell Katz
Journal:  N Engl J Med       Date:  2013-03-13       Impact factor: 91.245

6.  Individual differences in spatial pattern separation performance associated with healthy aging in humans.

Authors:  Shauna M Stark; Michael A Yassa; Craig E L Stark
Journal:  Learn Mem       Date:  2010-05-21       Impact factor: 2.460

Review 7.  Statins for the primary prevention of cardiovascular disease.

Authors:  Fiona Taylor; Kirsten Ward; Theresa Hm Moore; Margaret Burke; George Davey Smith; Juan-Pablo Casas; Shah Ebrahim
Journal:  Cochrane Database Syst Rev       Date:  2011-01-19

8.  Memory impairment, executive dysfunction, and intellectual decline in preclinical Alzheimer's disease.

Authors:  Ellen Grober; Charles B Hall; Richard B Lipton; Alan B Zonderman; Susan M Resnick; Claudia Kawas
Journal:  J Int Neuropsychol Soc       Date:  2008-03       Impact factor: 2.892

9.  Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer's disease in the presenilin 1 E280A kindred: a case-control study.

Authors:  Eric M Reiman; Yakeel T Quiroz; Adam S Fleisher; Kewei Chen; Carlos Velez-Pardo; Marlene Jimenez-Del-Rio; Anne M Fagan; Aarti R Shah; Sergio Alvarez; Andrés Arbelaez; Margarita Giraldo; Natalia Acosta-Baena; Reisa A Sperling; Brad Dickerson; Chantal E Stern; Victoria Tirado; Claudia Munoz; Rebecca A Reiman; Matthew J Huentelman; Gene E Alexander; Jessica B S Langbaum; Kenneth S Kosik; Pierre N Tariot; Francisco Lopera
Journal:  Lancet Neurol       Date:  2012-11-06       Impact factor: 44.182

10.  Clinical and biomarker changes in dominantly inherited Alzheimer's disease.

Authors:  Randall J Bateman; Chengjie Xiong; Tammie L S Benzinger; Anne M Fagan; Alison Goate; Nick C Fox; Daniel S Marcus; Nigel J Cairns; Xianyun Xie; Tyler M Blazey; David M Holtzman; Anna Santacruz; Virginia Buckles; Angela Oliver; Krista Moulder; Paul S Aisen; Bernardino Ghetti; William E Klunk; Eric McDade; Ralph N Martins; Colin L Masters; Richard Mayeux; John M Ringman; Martin N Rossor; Peter R Schofield; Reisa A Sperling; Stephen Salloway; John C Morris
Journal:  N Engl J Med       Date:  2012-07-11       Impact factor: 91.245
  10 in total
  312 in total

1.  The Road Ahead to Cure Alzheimer's Disease: Development of Biological Markers and Neuroimaging Methods for Prevention Trials Across all Stages and Target Populations.

Authors:  E Cavedo; S Lista; Z Khachaturian; P Aisen; P Amouyel; K Herholz; C R Jack; R Sperling; J Cummings; K Blennow; S O'Bryant; G B Frisoni; A Khachaturian; M Kivipelto; W Klunk; K Broich; S Andrieu; M Thiebaut de Schotten; J-F Mangin; A A Lammertsma; K Johnson; S Teipel; A Drzezga; A Bokde; O Colliot; H Bakardjian; H Zetterberg; B Dubois; B Vellas; L S Schneider; H Hampel
Journal:  J Prev Alzheimers Dis       Date:  2014-12

Review 2.  Neurology--the next 10 years.

Authors:  Ralf Baron; Donna M Ferriero; Giovanni B Frisoni; Chetan Bettegowda; Ziya L Gokaslan; John A Kessler; Annamaria Vezzani; Stephen G Waxman; Sven Jarius; Brigitte Wildemann; Michael Weller
Journal:  Nat Rev Neurol       Date:  2015-10-27       Impact factor: 42.937

3.  Upward drift in cerebrospinal fluid amyloid β 42 assay values for more than 10 years.

Authors:  Suzanne E Schindler; Courtney L Sutphen; Charlotte Teunissen; Lena M McCue; John C Morris; David M Holtzman; Sandra D Mulder; Philip Scheltens; Chengjie Xiong; Anne M Fagan
Journal:  Alzheimers Dement       Date:  2017-07-12       Impact factor: 21.566

Review 4.  The cholinergic system in the pathophysiology and treatment of Alzheimer's disease.

Authors:  Harald Hampel; M-Marsel Mesulam; A Claudio Cuello; Martin R Farlow; Ezio Giacobini; George T Grossberg; Ara S Khachaturian; Andrea Vergallo; Enrica Cavedo; Peter J Snyder; Zaven S Khachaturian
Journal:  Brain       Date:  2018-07-01       Impact factor: 13.501

Review 5.  Understanding mechanisms and seeking cures for Alzheimer's disease: why we must be "extraordinarily diverse".

Authors:  Madhav Thambisetty
Journal:  Am J Physiol Cell Physiol       Date:  2017-06-14       Impact factor: 4.249

Review 6.  Ethics of genetic and biomarker test disclosures in neurodegenerative disease prevention trials.

Authors:  Scott Y H Kim; Jason Karlawish; Benjamin E Berkman
Journal:  Neurology       Date:  2015-03-11       Impact factor: 9.910

Review 7.  Primary and Secondary Prevention Trials in Alzheimer Disease: Looking Back, Moving Forward.

Authors:  David Hsu; Gad A Marshall
Journal:  Curr Alzheimer Res       Date:  2017       Impact factor: 3.498

8.  Defining imaging biomarker cut points for brain aging and Alzheimer's disease.

Authors:  Clifford R Jack; Heather J Wiste; Stephen D Weigand; Terry M Therneau; Val J Lowe; David S Knopman; Jeffrey L Gunter; Matthew L Senjem; David T Jones; Kejal Kantarci; Mary M Machulda; Michelle M Mielke; Rosebud O Roberts; Prashanthi Vemuri; Denise A Reyes; Ronald C Petersen
Journal:  Alzheimers Dement       Date:  2016-09-30       Impact factor: 21.566

9.  Tau Accumulation in Clinically Normal Older Adults Is Associated with Hippocampal Hyperactivity.

Authors:  Willem Huijbers; Aaron P Schultz; Kathryn V Papp; Molly R LaPoint; Bernard Hanseeuw; Jasmeer P Chhatwal; Trey Hedden; Keith A Johnson; Reisa A Sperling
Journal:  J Neurosci       Date:  2018-11-27       Impact factor: 6.167

10.  Nonlinear Distributional Mapping (NoDiM) for harmonization across amyloid-PET radiotracers.

Authors:  Michael J Properzi; Rachel F Buckley; Jasmeer P Chhatwal; Michael C Donohue; Cristina Lois; Elizabeth C Mormino; Keith A Johnson; Reisa A Sperling; Aaron P Schultz
Journal:  Neuroimage       Date:  2018-11-17       Impact factor: 6.556
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.